This is the theme of the remarks made by Arnie Gundersen of Fairewinds Associates on DNA’s behalf at the recent Pickering relicensing hearing.
His remarks & thoughts on this are articulated in the most recent podcast on the Fairewinds Web site.

The podcast can be found here